Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.02 ▼ -0.46
(-5.42%)
MKT CAP: $3.63B • VOL: 21.05M
52W L $2 52W H $15
IOVA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $263.5M | $164.1M | $1.2M |
| YoY Revenue Growth % | +60.6% | +13699.0% | — |
| Gross Profit | $90.3M | $70.8M | — |
| Gross Margin % | 34.3% | 43.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$403.4M | -$395.3M | -$460.6M |
| Operating Margin % | -153.1% | -240.9% | -38735.0% |
| Net Income (GAAP) | -$391.0M | -$372.2M | -$444.0M |
| EBITDA (Normalized) | -$376.3M | -$386.4M | -$460.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$302.4M | -$353.0M | -$361.8M |
| Capital Expenditures (CapEx) | $33.8M | $11.1M | $53.5K |
| Free Cash Flow (FCF) | -$336.2M | -$364.0M | -$361.9M |
| FCF Margin % | -127.6% | -221.9% | -30435.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -25.3% |
| Cash & Short-Term Equivalents | $163.1M | $115.7M | — |
| Total Debt (Short + Long Term) | $96.6M | $90.0M | $557.3M |
| Total Stockholders' Equity | $698.6M | $710.4M | $1.14B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IOVA.